Objective To raise awareness of the growing list of non–platinum‐based chemo‐and
immunotherapeutic agents that have been associated with ototoxicity and to introduce the …

There continues to be a growing interest in pharmacology and ototoxicity within the
audiology community, the medical community, and with researchers throughout the world …

Purpose: Ototoxic medications and chemical agents in the workplace can put individuals'
hearing and vestibular health at risk for permanent injury. Proactive ototoxicity management …

Background: Nowadays, immunosuppressant drugs are widely used to prevent rejection in
organ transplantation and to treat autoimmune diseases. Ototoxicity related to …

A number of compounds have been identified as ototoxic in the literature. The degree of
ototoxicity can vary widely across agents, and occasionally an agent may be listed as …

Drug-induced hearing loss can occur secondary to a variety of clinical therapeutics,
including certain classes of antineoplastics, antimicrobials, diuretics, analgesics, and …

In this article, the known mechanism (s) of tumoricidal and ototoxic pathogenesis, the
reported clinical ototoxic and neurotoxic side effects, potential antidotes or inhibitory agents …

Ototoxicity monitoring is particularly critical in patients receiving platinum-based
chemotherapy or long-term aminoglycoside antibiotic administration. Furthermore, as new …

OBJECTIVE: To assess the long-term ototoxicity effect of platinum chemotherapy in a series
of pediatric patients. DESIGN: A prospective cohort study. METHODS: Patients who received …

In the past year, progress has been made not only in elucidating the mechanisms of
ototoxicity but also in finding otoprotective agents. For aminoglycosides, new dosing …